secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056940
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Q1 net loss $47.9M; MDD Phase 3 on track for H2 2024 start
----------------------------------------------------------------

- Net loss of $47.9M for Q1 2024, up from $41.7M in Q1 2023; cash and securities $885.4M.
- R&D expenses rose to $44.3M from $39.5M, driven by azetukalner manufacturing and personnel costs.
- Phase 3 MDD program to start H2 2024 after successful FDA interactions; X-TOLE2 enrollment completion expected late 2024 to early 2025.
- WHO and USAN approved 'azetukalner' as generic name for XEN1101, a Kv7 potassium channel opener.
- Other income increased to $11.5M from $7.6M on higher interest; cash expected to fund operations into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017024056940/0000950170-24-056940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017024056940/xene-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer